蛋白多肽類藥物脂質體是將蛋白多肽類藥物用脂質體包封后形成的載藥脂質體，具有靶向、緩釋、良好的穩(wěn)定性等優(yōu)點。綜述了2000年以來中國專利申請中涉及的新型蛋白多肽類藥物脂質體，包括凝膠型脂質體、前體脂質體、長循環(huán)脂質體、免疫脂質體、柔性脂質體、pH敏感脂質體、配體修飾脂質體、磁性納米脂質體、多囊脂質體，為繼續(xù)開發(fā)新型的蛋白多肽類藥物脂質體提供新的思路。

With the development of science and technology, electronic information technology has penetrated into many aspects of society now. Electronic informed consent is an effective way to adapt to development clinical trial. China is still at an early stage in this field. Affected by the outbreak of COVID-19 in 2020, the demand for electronic informed consent in clinical trial has become more urgent. Based on my own work experience, the author wants to analyze the problems in the traditional informed consent process and the current situations of electronic informed consent in China and explores the feasibility of electronic informed consent in clinical trials.